<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T04:39:03Z</responseDate>
  <request identifier="oai:figshare.com:article/32631825" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/32631825</identifier>
        <datestamp>2026-10-01T17:16:27Z</datestamp>
        <setSpec>portal_1172</setSpec>
        <setSpec>item_type_8</setSpec>
        <setSpec>month_year_10_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Identification and functional study of a novel bioactive peptide QUB-1761 from the venom of the Brazilian yellow scorpion, Tityus serrulatus</dc:title>
          <dc:creator>Xinyue Wang (286629)</dc:creator>
          <dc:subject>PUREID: 250509228</dc:subject>
          <dc:subject>Scorpion venom</dc:subject>
          <dc:subject>non-disulphide bridged peptide</dc:subject>
          <dc:subject>Gram-positive and Gram-negative bacteria</dc:subject>
          <dc:subject>human lung cancer</dc:subject>
          <dc:subject>haemolysis activity</dc:subject>
          <dc:description>Scorpion venom contains a variety of peptides exerting broad bioactivities. In this thesis, QUB-1761, a non-disulphide bridged peptide (NDBP), was discovered in the venom of the Brazilian yellow scorpion, Tityus serrulatus (T. serrulatus). The peptide was identified through molecular cloning by using a sense primer. The synthetic peptide was obtained by solid phase peptide synthesis (SPPS), followed by purification and confirmation through reversed-phase high performance liquid chromatography (RP-HPLC) and matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF MS). In broth microdilution assays, QUB-1761 had strong inhibitory effects on both Gram-positive and Gram-negative bacteria (MIC=8 µM for Staphylococcus aureus, MIC=32 µM for Escherichia coli). However, it was of low potency against yeast (MIC=128 µM for Candida albicans). In MTT anticancer cell proliferation and trypan blue exclusion assays, QUB-1761 beyond the concentration of 40 µM can completely kill the human lung cancer cells (NCI-H838). In terms of the haemolytic assays, QUB-1761 showed about 30% haemolysis activity at 64 µM and more than 50% at 128 µM. Nonetheless, QUB-1761 has the potential to be used in the design of drugs to treat bacterial infections or cancer if optimised.&lt;br&gt;&lt;br&gt;&lt;i&gt;Thesis embargoed until 31 December 2026&lt;/i&gt;.</dc:description>
          <dc:date>2026-10-01T17:16:27Z</dc:date>
          <dc:type>Text</dc:type>
          <dc:type>Thesis</dc:type>
          <dc:identifier>10.17034/32631825.v1</dc:identifier>
          <dc:relation>https://figshare.com/articles/thesis/Identification_and_functional_study_of_a_novel_bioactive_peptide_QUB-1761_from_the_venom_of_the_Brazilian_yellow_scorpion_Tityus_serrulatus/32631825</dc:relation>
          <dc:rights>All Rights Reserved</dc:rights>
          <dc:rights>Open Access after 2026-12-31</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
